FDG PET imaging in patients with pathologically verified dementia.

  title={FDG PET imaging in patients with pathologically verified dementia.},
  author={J. M. Hoffman and Kathleen Welsh-Bohmer and Michael W. Hanson and Barbara Crain and Christine Hulette and Nancy L Earl and R. Edward Coleman},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  volume={41 11},
UNLABELLED The purpose of this study was to confirm with pathologic verification 2 beliefs related to Alzheimer's disease (AD): (a) the long-standing impression that bilateral temporo-parietal hypometabolism, as noted on FDG PET imaging, is the metabolic abnormality associated with Alzheimer's disease (AD) and (b) that the sensitivity, specificity, and diagnostic accuracy of the metabolic pattern of bilateral temporo-parietal hypometabolism allows differentiation between other degenerative… CONTINUE READING
125 Citations
62 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 125 extracted citations


Publications referenced by this paper.
Showing 1-10 of 62 references

Application of the National Institute onAging (NIA)-Reagan Institute Criteria for the neuropathological diagnosis of Alzheimer disease

  • KL Newell, BT Hyman, JH Growden, ET. Hedley-Whyte
  • J Neuropathol Exp Neurol
  • 1999

Interpretation variability of 18 F - fluoro - 2 - deoxyglucose ( FDG ) positron emission tomography ( PET ) in demen

  • JM Hoffman, MW Hanson, KA Welsh
  • Invest Radiol .
  • 1996

Interpretation variability of 18F-fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) in dementia

  • JM Hoffman, MW Hanson, KA Welsh
  • Invest Radiol.1996;31:316–322
  • 1996

Similar Papers

Loading similar papers…